<DOC>
	<DOCNO>NCT01671982</DOCNO>
	<brief_summary>To assess drug concentration tenofovir ( TDF ) HIV-infected Thai adult moderate renal function impairment administer recommend dose 300 mg every 48 hour , alternative dose 150 mg every 24 hour .</brief_summary>
	<brief_title>ALternative TEnofovir Dosing Adults With Moderate Renal Function Impairment</brief_title>
	<detailed_description>The study design Phase I , non-randomized , open-label , pharmacokinetic study . We hypothesize administration tenofovir 150 mg daily HIV-infected Thai adult moderate renal function impairment ( CLcr 30 &lt; 50 mL/min ) provide comparable drug exposure current recommend dose 300 mg every 48 hour . Confirmed HIV-positive subject receive tenofovir ( TDF ) 300 mg , every 48 hour , part NNRTI-based lopinavir/ritonavir ( LPV/r ) -based HAART regimen propose participate . Subjects meeting require criterion enrol one 2 group depend HAART regimen : . Group 1 : Subjects receive tenofovir 300 mg , every 48 hour , combination lamivudine NNRTI , confirm CLcr 30 &lt; 50 mL/min Group 2 : Subjects receive tenofovir 300 mg , every 48 hour , combination lamivudine lopinavir/ritonavir , confirm CLcr 30 &lt; 50 mL/min The study procedures identical group . All subject enrol two study visit . At first visit , 48-hour pharmacokinetic evaluation perform . Immediately follow completion PK sampling , tenofovir dose change 150 mg , daily . Two week later , second visit , 24-hour pharmacokinetic evaluation perform . Following completion second PK sample tenofovir dose change back 300 mg every 48 hour . At time subject reach end study .</detailed_description>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>age &gt; 18 year old provide write informed consent receive tenofovir tablet formulation Thai Government Pharmaceutical Organization ( GPO ) least 4 week enrollment documentation confirm HIV1 infection ( document two serology test obtain two different date ) Confirmed Creatinine clearance result 30 &lt; 50 mL/min [ confirm defined two CLcr determination calculate use CockcroftGault equation within two week , within 1 month prior entry ] receive tenofovir 300 mg , every 48 hour least 2 week prior entry , combination 3TC plus NNRTI , 3TC plus lopinavir/ritonavir HIV1 RNA viral load &lt; 50 copies/mL within 6 month prior entry Concomitant use atazanavir , didanosine Pregnant Any follow laboratory test within 30 day prior study entry classify â‰¥ Grade 3 ( see DAIDS Table Grading Severity Adult Pediatric Adverse Events , Version 1.0 [ Dec. 2004 ] , Clarification August , 2009 ) : neutrophil count , hemoglobin , platelet , AST , ALT HBsantigen positive Any clinically significant disease ( HIV1 infection ) clinically significant finding screen medical history physical examination , investigator 's opinion , would compromise participation study concurrent participation clinical trial without prior agreement two study team</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>